title: Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.
authors.forename: Ridvan
authors.initials: R
authors.lastname: Ali
authors.forename: Fahir
authors.initials: F
authors.lastname: Ozkalemkas
authors.forename: Atilla
authors.initials: A
authors.lastname: Ozkan
authors.forename: Vildan
authors.initials: V
authors.lastname: Ozkocaman
authors.forename: Tulay
authors.initials: T
authors.lastname: Ozcelik
authors.forename: Ulku
authors.initials: U
authors.lastname: Ozan
authors.forename: Meral
authors.initials: M
authors.lastname: Kurt
authors.forename: Ahmet
authors.initials: A
authors.lastname: Tunali
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D005260:Female; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D010954:Plasmacytoma / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D011719:Pyrazines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib